Amicus Therapeutics, Inc.
FOLDDelisted Apr 27, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001178879
Amicus Therapeutics, Inc. was delisted on Apr 27, 2026; its insiders filed their last Form 4 on Apr 27, 2026; 298 institutions reported holding it in 13F filings for Q1 2026, worth $4.81B in total; Soros Fund Management was the only superinvestor holding it.
13F holders, Q3 2025
Institutional positions in Amicus Therapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 287
- +18 vs. Q2 2025
- Shares held
- 312.3M
- −3.92M (−1.2%) vs. Q2 2025
- Total value
- $2.46B
- +$647.9M (+35.7%) vs. Q2 2025
- New holders
- 51
- 108 more added
- Sold out
- 33
- 93 more reduced
3 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FOLD on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 2 | $11.5K |
| Q1 2026 | 298 | $4.81B |
| Q4 2025 | 332 | $4.57B |
| Q3 2025 | 287 | $2.46B |
| Q2 2025 | 272 | $1.83B |
| Q1 2025 | 286 | $2.55B |
| Q4 2024 | 290 | $2.88B |
| Q3 2024 | 293 | $3.31B |
| Q2 2024 | 259 | $3.13B |
| Q1 2024 | 254 | $3.79B |
| Q4 2023 | 229 | $4.53B |
| Q3 2023 | 229 | $3.63B |
| Q2 2023 | 216 | $3.86B |
| Q1 2023 | 226 | $3.30B |
| Q4 2022 | 230 | $3.57B |
| Q3 2022 | 222 | $3.05B |
| Q2 2022 | 213 | $3.28B |
| Q1 2022 | 216 | $2.87B |
| Q4 2021 | 224 | $3.48B |
| Q3 2021 | 238 | $2.80B |
| Q2 2021 | 235 | $2.67B |
| Q1 2021 | 259 | $2.74B |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Amicus Therapeutics, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Quadrature Capital Ltd | 0 | $0 | 0.00% | −44,512−100.0% | Sold out |
| Twinbeech Capital LP | 0 | $0 | 0.00% | −43,306−100.0% | Sold out |
| Advantage Alpha Capital Partners LP | 0 | $0 | 0.00% | −35,082−100.0% | Sold out |
| Sherbrooke Park Advisers LLC | 0 | $0 | 0.00% | −29,539−100.0% | Sold out |
| Wrapmanager Inc | 0 | $0 | 0.00% | −22,165−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −15,062−100.0% | Sold out |
| Ambassador Advisors, LLC | 0 | $0 | 0.00% | −14,420−100.0% | Sold out |
| 111 Capital | 0 | $0 | 0.00% | −13,355−100.0% | Sold out |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −8,309−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −5,210−100.0% | Sold out |
| Old Second National Bank of Aurora | 0 | $0 | 0.00% | −2,410−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −1,669−100.0% | Sold out |
| MB, Levis & Associates, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Geneos Wealth Management Inc. | 0 | $0 | 0.00% | −850−100.0% | Sold out |
| Barrow Hanley Mewhinney & Strauss LLC | 0 | $0 | 0.00% | −384−100.0% | Sold out |
| Point72 Asia (Singapore) Pte. Ltd. | 0 | $0 | 0.00% | −211−100.0% | Sold out |
| Danske Bank A/S | 0 | $0 | 0.00% | −172−100.0% | Sold out |
| Fortitude Family Office, LLC | 0 | $0 | 0.00% | −81−100.0% | Sold out |
| Assetmark, Inc | 0 | $0 | 0.00% | −64−100.0% | Sold out |
| Skopos Labs, Inc. | 0 | $0 | 0.00% | −22−100.0% | Sold out |
| Norges Bank | – | – | – | – | Not filed |
| E Fund Management Co., Ltd. | – | – | – | – | Not filed |
| CIBC World Markets Corp | – | – | – | – | Not filed |